Duodopa rejected for NHS use in Scotland

News

Author: Almaz OhenePublished: 11 January 2016

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

The advanced Parkinson’s treatment Duodopa has been rejected for routine use on the NHS in Scotland, sparking concerns among charities and health professionals.

The Scottish Medicines Consortium (SMC) said it was unable to approve of Duodopa, due to questions raised over its cost-effectiveness.

Dr Alan MacDonald, vice chairman of SMC, said: “The Committee was unable to accept co-careldopa intestinal gel (Duodopa) for the routine treatment of advanced Parkinson’s disease because of uncertainty about the clinical benefits the medicine would provide for this patient group in relation to its cost.”

Duodopa, which can help to control the symptoms of advanced Parkinson’s when all other treatments have stopped working. The gel treatment is administered to the intestine via pump and a tube and requires the patient to undergo surgery – it is estimated to cost around £28,000-per-year per patient and was approved for use by the NHS in England in July 2015.

Go Back

Share this story

Comments


Related articles


Mitch Faile

Global update

MUSIC VIDEO: Mitch Faile, the next Parkinson’s popstar?

The anthem people with Parkinson’s have been waiting for

READ MORE
A headshot of Professor Veerle Visser‐Vandewalle.

sponsored article

Advances

“Finding a DBS system to fit the needs of individual patients is crucial”

An innovation that could help people with Parkinson’s disease

READ MORE
Scientists working in a lab

Special reports

Prostate drug could “change the lives of people with Parkinson’s”

The drug could slow down and stop Parkinson’s progression

READ MORE